BeOne Medicines (NASDAQ:ONC) SVP Sells $3,739,118.40 in Stock

Key Points

• BeOne Medicines SVP Chan Henry Lee sold 10,671 shares for approximately $3.74 million on October 8th, which marks his latest transaction following three earlier stock sales this year.
• Shares of BeOne Medicines dropped 4.7% during midday trading, bringing the stock price to $320.10, while the company maintains a market cap of $35.08 billion.
• Despite reporting better-than-expected earnings of $0.84 EPS for the last quarter, analysts project a negative EPS of -5.82 for BeOne Medicines for the current year.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 10,671 shares of the stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $350.40, for a total transaction of $3,739,118.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, September 10th, Chan Henry Lee sold 10,006 shares of BeOne Medicines stock. The shares were sold at an average price of $325.53, for a total transaction of $3,257,253.18.
• On Wednesday, August 13th, Chan Henry Lee sold 11,013 shares of BeOne Medicines stock. The shares were sold at an average price of $300.45, for a total transaction of $3,308,855.85.
• On Wednesday, July 30th, Chan Henry Lee sold 920 shares of BeOne Medicines stock. The shares were sold at an average price of $304.60, for a total transaction of $280,232.00.

BeOne Medicines Trading Down 4.7%

Shares of NASDAQ:ONC traded down $15.70 during midday trading on Friday, hitting $320.10. 335,084 shares of the stock traded hands, compared to its average volume of 407,954. The stock has a market capitalization of $35.08 billion, a PE ratio of -185.03 and a beta of 0.31. The business's 50 day moving average is $322.42 and its two-hundred day moving average is $276.58. The company has a quick ratio of 1.72, a current ratio of 1.95 and a debt-to-equity ratio of 0.04. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $170.99 and a one year high of $355.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The firm had revenue of $1.32 billion during the quarter, compared to analysts' expectations of $1.24 billion. As a group, research analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Guggenheim upped their price target on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a research report on Thursday, August 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BeOne Medicines in a report on Wednesday. Morgan Stanley raised their price target on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a report on Friday, June 27th. Zacks Research raised BeOne Medicines from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 18th. Finally, Wall Street Zen upgraded shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research note on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $340.30.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds have recently made changes to their positions in the stock. Primecap Management Co. CA acquired a new position in BeOne Medicines during the second quarter worth $1,231,720,000. Temasek Holdings Private Ltd purchased a new stake in shares of BeOne Medicines during the second quarter worth approximately $244,603,000. Marshall Wace LLP purchased a new position in BeOne Medicines in the second quarter valued at approximately $113,190,000. Baird Financial Group Inc. purchased a new position in BeOne Medicines in the second quarter valued at approximately $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in BeOne Medicines in the second quarter valued at approximately $73,347,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.